Advertisement
U.S. markets open in 8 hours 32 minutes

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
57.34-1.03 (-1.76%)
At close: 04:00PM EDT
58.00 +0.66 (+1.15%)
After hours: 07:05PM EDT

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302 498 6700
https://www.incyte.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees2,524

Key Executives

NameTitlePayExercisedYear Born
Mr. Herve HoppenotCEO & Chairman2.89MN/A1960
Ms. Christiana Stamoulis MBAExecutive VP & CFO1.16MN/A1971
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive VP & GM of North America996.28k545.65k1958
Dr. Steven H. Stein M.D.Executive VP & Chief Medical Officer1.22MN/A1967
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & DevelopmentN/AN/A1963
Mr. Thomas TrayVP of Finance, Chief Accounting Officer & ControllerN/AN/A1978
Mr. Michael James MorrisseyExecutive VP & Head of Global Technical OperationsN/AN/A1964
Sheila A. DentonExecutive VP, General Counsel & Corporate SecretaryN/AN/A1966
Ms. Pamela M. MurphyVice President of Investor Relations & Corporate CommunicationsN/AN/A1951
Ms. Paula J. SwainExecutive Vice President of Human Resources611.92k4.21M1958
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Corporate Governance

Incyte Corporation’s ISS Governance QualityScore as of March 1, 2024 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.